#USA #oncology #South San Francisco #Precision Medicine #IDEAYA

IDEAYA Biosciences to Host Investor R&D Day Webcast

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a pioneering company in precision medicine focused on oncology, has officially announced the agenda for its anticipated Investor R&D Day. This online event is scheduled for December 16, 2024, from 8:00 AM to 9:30 AM ET, and aims to provide investors and stakeholders with critical insights into the company's innovative research and ongoing clinical development initiatives.

Overview of the Event

The Investor R&D Day will feature presentations from IDEAYA's management team alongside leading experts in the field. The primary focus will be on showcasing the company’s precision oncology pipeline, which aims to revolutionize treatment options through targeted therapies. IDEAYA’s commitment to addressing significant medical needs through scientific advancements will be at the forefront of this webcast.

Key Topics on the Agenda

The agenda for the day includes a series of in-depth discussions, including but not limited to:

• - Establishing a Global Leader in Precision Medicine Oncology: Insights into IDEAYA's strategic vision and operational roadmap.
• - Uveal Melanoma Roundtable: A focused discussion on treatment paradigms and advancements in managing uveal melanoma.
• - Tumor Heterogeneity and Drug Resistance: Exploring innovative strategies to tackle these critical challenges in cancer treatment.
• - IDEAYA and GSK Collaboration: Updates on the exciting partnership with GSK concerning the development of potential new treatments.

The presentations will spotlight several of IDEAYA's pipeline programs, notably:

• - IDE275 / GSK959: A potential future leader in Werner Helicase inhibition in Phase 1 trials.
• - IDE892: A promising candidate targeting the MTA-cooperative PMRT5 pathway.
• - IDE034: A bispecific antibody-drug conjugate focusing on B7H3/PTK7 targeting.
• - KAT6/7 Development Candidate: A novel approach involving lysine acetyltransferases.

Notable Guest Speakers

The event will also feature contributions from respected figures in oncology, including:

• - Dr. Carol Shields: Chief of the Ocular Oncology service at Wills Eye Hospital.
• - Dr. Kornelia Polyak: Renowned cancer researcher from the Dana-Farber Cancer Institute.
• - Dr. Timothy Yap: Expert in investigational cancer therapeutics from MD Anderson.

Registration and Participation

For those interested in participating, registration is Currently Open. Investors can access the webcast through IDEAYA's Investor Relations portal, found on their official website. Presentations will be available for viewing shortly before the event, allowing stakeholders to align their schedules accordingly.

About IDEAYA Biosciences

Founded with the vision of becoming a front-runner in precision oncology, IDEAYA Biosciences leverages genetic insights to discover and develop targeted therapeutics. The company's unique approach combines modern drug discovery with the capabilities necessary to identify relevant biomarkers, ultimately selecting patient populations primed for success with their therapies. Through this integrated strategy, IDEAYA aims to not only improve outcomes for cancer patients but to pave the way for advancements in precision medicine across the industry.

Conclusion

The upcoming Investor R&D Day represents an excellent opportunity for stakeholders to gain insights into IDEAYA's ongoing projects and future directions. As the field of precision oncology continues to evolve, IDEAYA's innovative approaches are set to play a crucial role in shaping the future of cancer treatment. Don't miss the chance to witness the live presentations, discussions, and opportunities for engagement with leaders in the field.